<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>87(11)</volume><submitter>Arrambide G</submitter><pubmed_abstract>&lt;h4>Objective&lt;/h4>To determine the prognostic value of selected biomarkers in clinically isolated syndromes (CIS) for conversion to multiple sclerosis (MS) and disability accrual.&lt;h4>Methods&lt;/h4>Data were acquired from 2 CIS cohorts. The screening phase evaluated patients developing clinically definite MS (CIS-CDMS) and patients who remained as CIS during a 2-year minimum follow-up (CIS-CIS). We determined levels of neurofascin, semaphorin 3A, fetuin A, glial fibrillary acidic protein, and neurofilament light (NfL) and heavy chains in CSF (estimated mean [95% confidence interval; CI]). We evaluated associations between biomarker levels, conversion, disability, and magnetic resonance parameters. In the replication phase, we determined NfL levels (n = 155) using a 900 ng/L cutoff. Primary en</pubmed_abstract><journal>Neurology</journal><pagination>1076-84</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC5027802</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Neurofilament light chain level is a weak risk factor for the development of MS.</pubmed_title><pmcid>PMC5027802</pmcid><pubmed_authors>Tur C</pubmed_authors><pubmed_authors>Vidal-Jordana A</pubmed_authors><pubmed_authors>Comabella M</pubmed_authors><pubmed_authors>Eixarch H</pubmed_authors><pubmed_authors>Kuhle J</pubmed_authors><pubmed_authors>Galan I</pubmed_authors><pubmed_authors>Alvarez-Cermeno JC</pubmed_authors><pubmed_authors>Sastre-Garriga J</pubmed_authors><pubmed_authors>Picon C</pubmed_authors><pubmed_authors>Nos C</pubmed_authors><pubmed_authors>Pareto D</pubmed_authors><pubmed_authors>Rovira A</pubmed_authors><pubmed_authors>Villar LM</pubmed_authors><pubmed_authors>Auger C</pubmed_authors><pubmed_authors>Tintore M</pubmed_authors><pubmed_authors>Arrambide G</pubmed_authors><pubmed_authors>Espejo C</pubmed_authors><pubmed_authors>Rio J</pubmed_authors><pubmed_authors>Kappos L</pubmed_authors><pubmed_authors>Montalban X</pubmed_authors><pubmed_authors>Arevalo MJ</pubmed_authors><pubmed_authors>Disanto G</pubmed_authors><pubmed_authors>Simon E</pubmed_authors><pubmed_authors>Castillo J</pubmed_authors></additional><is_claimable>false</is_claimable><name>Neurofilament light chain level is a weak risk factor for the development of MS.</name><description>&lt;h4>Objective&lt;/h4>To determine the prognostic value of selected biomarkers in clinically isolated syndromes (CIS) for conversion to multiple sclerosis (MS) and disability accrual.&lt;h4>Methods&lt;/h4>Data were acquired from 2 CIS cohorts. The screening phase evaluated patients developing clinically definite MS (CIS-CDMS) and patients who remained as CIS during a 2-year minimum follow-up (CIS-CIS). We determined levels of neurofascin, semaphorin 3A, fetuin A, glial fibrillary acidic protein, and neurofilament light (NfL) and heavy chains in CSF (estimated mean [95% confidence interval; CI]). We evaluated associations between biomarker levels, conversion, disability, and magnetic resonance parameters. In the replication phase, we determined NfL levels (n = 155) using a 900 ng/L cutoff. Primary en</description><dates><release>2016-01-01T00:00:00Z</release><publication>2016 Sep</publication><modification>2026-06-11T04:11:09.582Z</modification><creation>2025-05-18T10:29:11.821Z</creation></dates><accession>S-EPMC5027802</accession><cross_references><pubmed>27521440</pubmed><doi>10.1212/WNL.0000000000003085</doi></cross_references></HashMap>